Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can change how it is perceived. Furthermore, he comments on the uncertainty Brexit brings to the industry and how healthcare should be the number one priority going forward.
What were your experiences of transitioning from your previous role as market access director at AbbVie to becoming head of the British affiliate of Lupin? What are some of the challenges you had to overcome?
"We are building specialist capabilities in the UK with a focus on market access and we also lead several access projects across Europe from the UK office."
